SIGA Technologies, Inc.
SIGA
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $236.0M
$3.29
▲ +1.86%
P/E
-75.46
Mkt Cap
$236.0M
52-Wk Range
$2.83–$9.45
52-Week Range
$2.83 - $9.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 62.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- FDA-approved TPOXX with exclusive market position in smallpox treatment
- Strategic partnership with Cipla Therapeutics for expanded drug development
- Specialized focus on biodefense and health security with limited direct competition
- Government contracts and stockpiling programs providing stable revenue streams
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Increased government spending on biodefense and pandemic preparedness
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Falling
-24.0% over 3m
Quality
Strong
Solid business
Dividend
High yield
18.24% yield
Smart-money signal
Who's buying SIGA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Most recent quarter reported revenue of $41.0M (-49% YoY). Reported EPS of $0.17. Gross margin -8.1%.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
-30%
-72%
+272%
-74%
-95%
-11%
-49%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.0M
$81.5M
$7.0M
$81.1M
$2.6M
$3.8M
$6.2M
$41.0M
Margins · last 8Q
Gross
-8.1%
Operating
33.9%
Profit
30.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How SIGA stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related